Novavax, Inc., together with its subsidiary, Novavax AB, a late-stage biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases. The company's lead vaccine candidates include ResVax, a respiratory syncytial virus (RSV) fusion (F) protein recombinant nanoparticle vaccine with aluminum phosphate as an adjuvant that is in Phase III clinical trial to protect infants from RSV disease through maternal immunization; and NanoFlu, which is in Phase II clinical trial for treating seasonal influenza in older adults. Its lead adjuvant is Matrix-M that is used to enable a vaccine to enhance the amplitude of the immune response and qualitatively change it, and the immune systems attack against microorganisms, as well as allows immunization with much lower doses of antigen. The company also develops RSV F vaccine for older adults in Phase II clinical trial, and healthy children between two and six years of age in Phase I clinical trial. In addition, it develops nanoparticle vaccine candidates for clinic testing against ebola virus in Phase I clinical trial, as well as MERS coronavirus in animals; and combination respiratory vaccine to protect against influenza and RSV. The company has a clinical development agreement with Bill & Melinda Gates Foundation. Novavax, Inc. was founded in 1987 and is headquartered in Gaithersburg, Maryland.
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryBiotechnology
SectorMedical
Phone240-268-2000
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$34.29 million
Profitability
Miscellaneous
Employees374
Next Earnings Date5/8/2019 (Estimated)
OptionableOptionable
Novavax (NASDAQ:NVAX) Frequently Asked Questions
What is Novavax's stock symbol?
Novavax trades on the NASDAQ under the ticker symbol "NVAX."
How were Novavax's earnings last quarter?
Novavax, Inc. (NASDAQ:NVAX) posted its quarterly earnings data on Monday, March, 18th. The biopharmaceutical company reported ($0.13) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.12) by $0.01. The biopharmaceutical company earned $6.13 million during the quarter, compared to analysts' expectations of $7.87 million. During the same period in the previous year, the company posted ($0.16) earnings per share. View Novavax's Earnings History.
When is Novavax's next earnings date?
What price target have analysts set for NVAX?
8 Wall Street analysts have issued 12 month price targets for Novavax's shares. Their predictions range from $1.00 to $4.50. On average, they expect Novavax's stock price to reach $2.9538 in the next twelve months. This suggests a possible upside of 466.3% from the stock's current price. View Analyst Price Targets for Novavax.
What is the consensus analysts' recommendation for Novavax?
8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Novavax in the last year. There are currently 2 sell ratings, 1 hold rating and 5 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Novavax.
What are Wall Street analysts saying about Novavax stock?
Here are some recent quotes from research analysts about Novavax stock:
- 1. According to Zacks Investment Research, "NOVAVAX INC is a specialty biopharmaceutical company engaged in the research, development and commercialization of proprietary products focused on women's health and infectious diseases. Their technology platforms involve the use of proprietary, microscopic, organized, non-phospholipid structures as vehicles for the delivery of a wide variety of drugs and other therapeutic products, including certain hormones, anti-bacterial and anti-viral products and vaccine adjuvants. " (4/2/2019)
- 2. HC Wainwright analysts commented, "We have a Buy rating and 12-month price target of $6. We’ve used a discounted cash flow (DCF) methodology based on projected 2020-2030 revenues from sales of to arrive at our 12-month price target of $6 for NVAX shares (25% discount rate and 2% terminal growth rate)." (2/28/2019)
- 3. Cantor Fitzgerald analysts commented, ": We reaffirm our Neutral rating and $2 PT on NVAX. We believe the company’s portfolio of vaccine candidates has the potential to meaningfully improve the prevention of important infectious diseases. We think the forthcoming release of top-line data from the ResVax Phase 3 trial may be an important catalyst for the stock with the potential to de-risk the company’s most- advanced asset. In our view, understanding the need for and access to additional capital to develop pipeline assets while retaining their potential value is key to evaluating the fair value of the stock." (1/29/2019)
Has Novavax been receiving favorable news coverage?
Media stories about NVAX stock have trended somewhat positive on Sunday, according to InfoTrie. The research group ranks the sentiment of press coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Novavax earned a daily sentiment score of 1.2 on InfoTrie's scale. They also gave news stories about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the stock's share price in the near future.
Are investors shorting Novavax?
Novavax saw a decline in short interest during the month of March. As of March 29th, there was short interest totalling 91,991,465 shares, a decline of 2.7% from the March 15th total of 94,499,088 shares. Based on an average trading volume of 22,059,109 shares, the short-interest ratio is presently 4.2 days. Currently, 19.8% of the company's shares are short sold. View Novavax's Current Options Chain.
Who are some of Novavax's key competitors?
Some companies that are related to Novavax include BioCryst Pharmaceuticals (BCRX), Twist Bioscience (TWST), Cellectis (CLLS), NanoString Technologies (NSTG), Vericel (VCEL), Nightstar Therapeutics (NITE), BAVARIAN NORDIC/S (BVNRY), Osiris Therapeutics (OSIR), Voyager Therapeutics (VYGR), MeiraGTx (MGTX), Heska (HSKA), Acorda Therapeutics (ACOR), DBV TECHNOLOGIE/S (DBVT), Mesoblast (MESO) and Avrobio (AVRO).
What other stocks do shareholders of Novavax own?
Who are Novavax's key executives?
Novavax's management team includes the folowing people:
- Mr. Stanley Charles Erck, Pres, CEO & Director (Age 71)
- Mr. John Joseph Trizzino, Sr. VP, Chief Bus. Officer, CFO & Treasurer (Age 59)
- Mr. John A. Herrmann III, Sr. VP, Gen. Counsel & Corp. Sec. (Age 53)
- Dr. Gregory M. Glenn, Pres of R&D (Age 65)
- Ms. Erika S. Trahan, Sr. Mang. of Investor & PR
Who are Novavax's major shareholders?
Novavax's stock is owned by many different of institutional and retail investors. Top institutional investors include Wedbush Securities Inc. (0.01%) and DAVENPORT & Co LLC (0.01%). Company insiders that own Novavax stock include Barclay A Phillips, Gregory M Glenn, James F Young, John Trizzino, Michael A Mcmanus Jr, Rachel K King and Stanley C Erck. View Institutional Ownership Trends for Novavax.
Which major investors are buying Novavax stock?
NVAX stock was acquired by a variety of institutional investors in the last quarter, including DAVENPORT & Co LLC and Wedbush Securities Inc.. Company insiders that have bought Novavax stock in the last two years include Barclay A Phillips, Gregory M Glenn, John Trizzino, Michael A Mcmanus Jr, Rachel K King and Stanley C Erck. View Insider Buying and Selling for Novavax.
How do I buy shares of Novavax?
Shares of NVAX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Novavax's stock price today?
One share of NVAX stock can currently be purchased for approximately $0.5216.
How big of a company is Novavax?
Novavax has a market capitalization of $244.87 million and generates $34.29 million in revenue each year. The biopharmaceutical company earns $-184,750,000.00 in net income (profit) each year or ($0.50) on an earnings per share basis. Novavax employs 374 workers across the globe.
What is Novavax's official website?
How can I contact Novavax?
Novavax's mailing address is 20 FIRSTFIELD ROAD, GAITHERSBURG MD, 20878. The biopharmaceutical company can be reached via phone at 240-268-2000 or via email at [email protected]
MarketBeat Community Rating for Novavax (NASDAQ NVAX)
MarketBeat's community ratings are surveys of what our community members think about Novavax and other stocks. Vote "Outperform" if you believe NVAX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NVAX will underperform the S&P 500 over the long term. You may vote once every thirty days.
